Pittsburgh Business Times - by Kris B. Mamula
Date: Thursday, August 18, 2011, 9:24am EDT
Canonsburg-based generic drug maker Mylan Inc. has been sued by Endo Pharmaceuticals in connection with the filing of a Food and Drug Administration application to market the generic version of Frova, which is used to treat migraine headaches, Mylan announced.
Mylan believes it is the first company to file an application to market the prescription drug, giving the company 180 days of marketing exclusivity after FDA approval. Chadds Ford Pa.-based Endo filed the lawsuit in the U.S. District Court for the District of Delaware.
For the year ending June 30, Endo had total Frova sales of $68.2 million, according to IMS Health Inc. Mylan has 162 applications pending FDA approval, representing $94.4 billion in possible annual sales. Of those applications, 43 are potential first-to-file opportunities, representing $25.5 billion in possible annual brand sales for the year ending June 30, according to Danbury Conn.-IMS Health, which tracks pharmaceutical sales data and trends.
“Health is the greatest gift, contentment the greatest wealth, faithfulness the best relationship.” Buddha[/color][/i]